Question: I'm planning to travel abroad. Are there any considerations I should be aware of regarding my statin medication and travel?

Answer: Absolutely, there are a few things you should consider when traveling with statin medication:

1. **Medication Supply:** Make sure you have enough medication to last your entire trip. It's also a good idea to bring a little extra in case of travel delays.

2. **Storage:** Statins should be stored in a cool, dry place. If you're traveling to a hot or humid location, consider using a travel case with a cooling element.

3. **Time Zones:** If you're crossing time zones, you might need to adjust the time you take your medication. It's best to discuss this with your doctor or pharmacist.

4. **Travel Insurance:** Check if your travel insurance covers your medication and any potential health issues related to your condition.

5. **Local Healthcare:** Research the healthcare facilities at your destination. Know where to go if you need medical assistance.

6. **Prescription Documentation:** Carry a copy of your prescription and a letter from your doctor explaining your medication. This can be helpful for airport security and in case you need medical help abroad.

Remember, it's always best to discuss your travel plans with your healthcare provider. They can give you specific advice based on your health condition and the medication you're taking. Safe travels!
Sources:
page_content='and atorvastatin therapy. Pharmacoepidemiol Drug Saf  19, 75-81 (2010).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='therapy (i.e., fluvastatin plus nonstatin \nguideline-  directed medical therapy)3Moderate The potential for drug–  drug \ninteractions and dose limits \nbased on renal and hepatic \nfunction should be evaluated prior \nto initiating a statin. The effects \nof drug–  drug interactions may be \nmore pronounced, resulting in a \nhigher risk of myopathy\nCYP2C9 poor metabolizer AS 0.5 and 0 Increased fluvastatin exposure \nas compared with normal and \nintermediate metabolizer, which may \ntranslate to increased myopathy riskPrescribe ≤20\xa0mg per day as a starting \ndose and adjust doses of fluvastatin \nbased on disease-  specific guidelines. \nIf dose >20\xa0mg needed for desired \nefficacy, consider an alternative \nstatin or combination therapy (i.e., \nfluvastatin plus nonstatin guideline-  \ndirected medical therapy)3Moderate The potential for drug–  drug \ninteractions and dose limits \nbased on renal and hepatic \nfunction should be evaluated prior \nto initiating a statin. The effects' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Page 16 of 28Accepted Manuscript\n16 \n risk, clopidogrel resistance, or statin muscle toxicity. These pharmacogenetic applications are \nsignificant in terms of bot h healthcare efficacy and pharmaco -economic impact, but further changes \nin clinical practices are still needed for widespread use. Finally, other tests whose levels of evidence  \nare still insufficient can be expected to be developed in the future. Potential ly they will concern \ndirect -action oral anticoagulants, aspirin, beta -blockers, or converting enzyme inhibitors.  \n \n \nDisclosure of interest  \nThe authors declare they have no conflict of interest  concerning this article.' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}
page_content='other) genes, in addition to epigenetic, drug-  drug-  gene, and gene- \nenvironment interactions in statin therapies.\nDRUGS: STATINS (HMG-  CoA REDUCTASE INHIBITORS)\nBackground\nOne in four Americans aged 40 and older use a statin.24 In 2018, \natorvastatin and simvastatin were the #1 and #10 most commonly prescribed drugs in the United States, respectively. Statins have \na wide therapeutic index. The most common statin-  related ad -\nverse drug reaction is skeletal muscle toxicity which manifest \nas SAMS.25 SAMS include a range of clinical entities from the \nmost common (about 1 in 10), myalgia (pain without evidence of \nmuscle degradation, i.e., creatine kinase levels <\xa03× normal); less \ncommon (about 1 in 2,000), myopathy (evidence of muscle deg -\nradation with or without myalgia, i.e., creatine kinase levels ≥3× \nnormal); and rare (less than 1 in 10,000), rhabdomyolysis (severe \nmuscle damage with risk for acute kidney injury).26 Based on ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='and dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\n (Continued)\nCPIC UPDATE' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='continuation, thus leading to higher cholesterol levels and a higher \nrisk for cardiovascular disease if statins are not reinitiated.29,30\nLinking genetic variability to variability in drug-  related \nphenotypes\nWe applied a systematic approach to reviewing the evidence un -\nderlying the clinical validity of genetic associations with statin- \nrelated phenotypes including statin pharmacokinetics ( in vivo  \nand in vitro ), SAMS, hepatotoxicity, lab-  based efficacy (choles -\nterol lowering), and clinical efficacy (vascular event reduction). \nStatins evaluated included simvastatin, rosuvastatin, pravastatin, \npitavastatin, atorvastatin, fluvastatin, and lovastatin. We reviewed \nthe evidence for SLCO1B1 , ABCG2 , CYP2C9 , CYP3A4/5 , and \nHMGCR  and applied a grading system for each piece of evi -\ndence that evaluated an association between genotype and phe -\nnotype ( Tables\xa0 S1–  S5). We found the highest levels of evidence \nfor SLCO1B1  (all statins), ABCG2  (rosuvastatin), and CYP2C9' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='to initiating a statin. The effects \nof drug–  drug interactions may be \nmore pronounced, resulting in a \nhigher risk of myopathy\nAS, activity score.\n aRating scheme described in the Supplemental Material .\nCPIC UPDATE' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='gemfibrozil increases systemic exposure to active simvastatin acid (36) placing patients at increased risk for developing myopathy. Because of interactions such as these, all the statin package labels recommend reducing the dose of statins in patients using concomitant medications known to alter its pharmacokinetics.   The Role of Ancestry.  There is some evidence that Asian Americans are one of three important groups with an elevated risk/benefit ratio for use of some statins compared to other ancestry groups; the other important groups were patients on cyclosporine (CSA)/immune suppression and patients with severe kidney failure) (37-43).Geographic differences in allele frequency for SLCO1B1 rs4149056 (c.521T>C) do not appear to contribute to this sensitivity in Asians (44). For rosuvastatin, this difference appears to be at least partly attributable to variability in efflux transporters such as ABCG2, as well as gene-gene and gene-environment interactions not yet defined (45).  For' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='However, given the increasing shift towards panel-  based testing \nfor multiple pharmacogenes, and the vast number of individuals \nalready receiving statin therapy, an important issue to consider \nis how to manage statin therapy for patients that may already \nbe receiving statin therapy, and then receive a genotype result, \nparticularly for those whose genotype indicates that they are in \na higher risk category based on the currently prescribed statin \n(i.e., moderate or high SAMS risk in Figure\xa0 1). For patients with \nSLCO1B1 genotype-  statin dose combinations that fall within \nthe moderate SAMS risk categories in Figure\xa0 1 who have already \nbeen on a stable statin and dose for at least 4\xa0weeks without any \nsymptoms suggestive of SAMS, then it is reasonable to continue \nthat statin and dose long-  term.34 If those patients have been \nreceiving that statin therapy for less than 4\xa0weeks, then clinicians \nmay consider changing to a lower SAMS risk statin/dose in order' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='27. Abd, T.T. & Jacobson, T.A. Statin-  induced myopathy: a review and \nupdate. Expert Opin. Drug Saf. 10 , 373–  387 (2011).\n 28. Buettner, C., Rippberger, M.J., Smith, J.K., Leveille, S.G., Davis, R.B. \n& Mittleman, M.A. Statin use and musculoskeletal pain among adults \nwith and without arthritis. Am. J. Med. 125, 176–  182 (2012).\n 29. Serban, M.C. et al. Statin intolerance and risk of coronary heart \nevents and all-  cause mortality following myocardial infarction. J. \nAm. Coll. Cardiol.  69, 1386–  1395 (2017). 30. Cohen, J.D., Brinton, E.A., Ito, M.K. & Jacobson, T.A. \nUnderstanding Statin Use in America and Gaps in Patient \nEducation (USAGE): an internet-  based survey of 10,138 current \nand former statin users. J. Clin. Lipidol. 6 , 208–  215 (2012).\n 31. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, \nP.J. & Niemi, M. ABCG2 polymorphism markedly affects the \npharmacokinetics of atorvastatin and rosuvastatin. Clin. \nPharmacol. Ther.  86, 197–  203 (2009).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: I take Reditrex for my rheumatoid arthritis. My doctor has prescribed Crestor for my cholesterol. I am worried that there is some association between my arthritis and cholesterol drugs, what should I do?

Answer: Hello! It's great that you're being proactive about your health. Crestor, also known as rosuvastatin, is a medication often used to manage cholesterol levels. It works by reducing the amount of cholesterol produced by the liver and helping the liver to remove more cholesterol from the blood.

Reditrex, on the other hand, is a medication used to treat rheumatoid arthritis. It works by reducing the activity of the immune system, which can help decrease inflammation and pain in the joints.

While both of these medications are used to manage different conditions, it's important to discuss any concerns you have with your doctor. They can provide you with the most accurate information based on your specific health history and current medications. 

In some cases, certain medications can interact with each other, which is why it's crucial to keep your healthcare provider informed about all the medications you're taking. However, there's no widely recognized interaction between Crestor and Reditrex. 

Remember, if you experience any new or worsening symptoms after starting a new medication, it's important to contact your healthcare provider right away. They can help determine whether these symptoms are a side effect of the medication or due to something else. 

Please note that this advice is intended to be general in nature, and specific causes may not apply to your situation. Always consult with your healthcare provider for accurate information.
Sources:
page_content='adult patients with homozygous familial hypercholesterolemia.  \n1.6 Slowing of the Progression of Atherosclerosis \nCRESTOR is indicated as adjunctive therapy to diet to slow the progression of atheroscler osis in \nadult patients as part of a treatment strategy to lower Total -C and LDL -C to target levels.  \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='other) genes, in addition to epigenetic, drug-  drug-  gene, and gene- \nenvironment interactions in statin therapies.\nDRUGS: STATINS (HMG-  CoA REDUCTASE INHIBITORS)\nBackground\nOne in four Americans aged 40 and older use a statin.24 In 2018, \natorvastatin and simvastatin were the #1 and #10 most commonly prescribed drugs in the United States, respectively. Statins have \na wide therapeutic index. The most common statin-  related ad -\nverse drug reaction is skeletal muscle toxicity which manifest \nas SAMS.25 SAMS include a range of clinical entities from the \nmost common (about 1 in 10), myalgia (pain without evidence of \nmuscle degradation, i.e., creatine kinase levels <\xa03× normal); less \ncommon (about 1 in 2,000), myopathy (evidence of muscle deg -\nradation with or without myalgia, i.e., creatine kinase levels ≥3× \nnormal); and rare (less than 1 in 10,000), rhabdomyolysis (severe \nmuscle damage with risk for acute kidney injury).26 Based on ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR CYP3A5) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] Using these search terms, 1023 publications were identified. Study inclusion criteria included publications that incorporated analyses for the association between SLCO1B1, ABCG2, CYP2C9, HMGCR, or CYP3A4/5 genotypes and statins pharmacokinetic parameters as well as clinical outcomes. Non-English manuscripts and reviews were excluded. Following the application of these inclusion and exclusion criteria, 197 publications were reviewed and included in the evidence table (Table S1 to S5).  AVAILABLE GENETIC TEST OPTIONS  Desirable characteristics of pharmacogenetic tests, including naming of alleles and test report contents, have been' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='33  \nPATIENT INFORMATION  \nCRESTOR®(Kres-tor) \nrosuvastatin calcium  \nTablets  \nRead this Patient Information carefully before you start taking CRESTOR and each \ntime you get a refill. If you have any questions about CRESTOR, ask your doctor. \nOnly your doctor can determine if CRESTOR is right for you.  \nWhat is CRESTOR?  \nCRESTOR is a prescription medicine that contains a cholesterol -lowering medicine \ncalled rosuvastatin calcium . Most of the cholesterol in your blood is made in the liver. \nCRESTOR works by reducing cholesterol in two ways: CRESTOR blocks an  enzyme in \nthe liver causing the liver to make less cholesterol, and CRESTOR increases the \nuptake and breakdown by the liver of cholesterol already in the blood.  \n \n• CRESTOR is used along with diet to:  \no lower the level of your “bad” cholesterol (LDL)  \no increase the level of your “good” cholesterol (HDL)  \no lower the level of fat in your blood (triglycerides)' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='In a 12-week controlled study in boys and postmenarche al girls  10 to 17 years of age with \nheterozygous familial hypercholesterolemia  with CRESTOR 5  to 20 mg daily [see Use in \nSpecific Populations (8.4)  and Clinical Studies (14.7) ], elevations in serum creatine \nphosphokinase (CK)  >10 x ULN were observed more frequently in rosuvastatin compared with \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='10 Table  2. Adverse Reactions1 Reported in ≥2% of Patients Treated with \nCRESTOR and >  Placebo in the METEOR Trial (% of Patients)  \nAdverse Reactions  CRESTOR 40  mg  \nN=700  Placebo  \nN=281  \nMyalgia  12.7 12.1 \nArthralgia  10.1 7.1 \nHeadache  6.4 5.3 \nDizziness  4.0 2.8 \nIncreased CPK  2.6 0.7 \nAbdominal pain  2.4 1.8 \nALT > 3x ULN2 2.2 0.7 \n1 Adverse reactions by MedDRA preferred term.  \n2 Frequen cy recorded as abnormal laboratory value.  \n \nIn the JUPITER study, 17,802 participants were treated with rosuvastatin 20 mg (n=8901) or \nplacebo (n=8901) for a mean duration of 2 years. A higher percentage of rosuvastatin-treated \npatients versus placebo-treat ed patients, 6.6% and 6.2%, respectively, discontinued study \nmedication due to an adverse event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to treatment discontinuation.  \nIn JUPITER, there was a significantly  higher frequency of diabetes mellitus reported in patients' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='3 FULL PRESCRIBING INFORMATION \n1 INDICATIONS AND USAGE  \n1.1 Hyperlipidemia and Mixed Dyslipidemia \nCRESTOR is indicated as adjunctive therapy t o diet to reduce elevated Total -C, LDL -C, ApoB, \nnonHDL -C, and triglycerides and to increase HDL -C in adult patients with primary \nhyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet \nrestricted in saturated fat and cholesterol when response to diet and nonpharma cological \ninterventions alone has been inadequate.  \n1.2 Pediatric Patients with Familial Hypercholesterolemia  \nCRESTOR is indicated as an adjunct to diet to:  \n• reduce Total -C, LDL -C and ApoB levels in children and adolescent s 8 to17 years of age \nwith heteroz ygous familial hypercholesterolemia if after an adequate trial of diet therapy \nthe follow ing findings are present: LDL -C >190 mg/dL , or >160 mg/dL along with a' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1007The Clinical Pharmacogenetics Implementation \nConsortium Guideline for SLCO1B1, ABCG2, \nand CYP2C9 genotypes and Statin- Associated \nMusculoskeletal Symptoms\nRhonda M. Cooper- DeHoff1,2,†, Mikko Niemi3,4,5,†, Laura B. Ramsey6,7, Jasmine A. Luzum8,  \nE. Katriina T arkiainen3,4,5, Robert J. Straka9, Li Gong10, Sony T uteja11, Russell A. Wilke12, Mia W adelius13, \nEric A. Larson12, Dan M. Roden14,15, T eri E. Klein10, Sook W ah Y ee16, Ronald M. Krauss17, Richard M. T urner18, \nLatha Palaniappan19, Andrea Gaedigk20, Kathleen M. Giacomini16, Kelly E. Caudle21 and Deepak V oora22,*\nStatins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed \nmedications in the world. Statin-  associated musculoskeletal symptoms (SAMS) impact statin adherence and \nultimately can impede the long-  term effectiveness of statin therapy. There are several identified pharmacogenetic' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='27. Abd, T.T. & Jacobson, T.A. Statin-  induced myopathy: a review and \nupdate. Expert Opin. Drug Saf. 10 , 373–  387 (2011).\n 28. Buettner, C., Rippberger, M.J., Smith, J.K., Leveille, S.G., Davis, R.B. \n& Mittleman, M.A. Statin use and musculoskeletal pain among adults \nwith and without arthritis. Am. J. Med. 125, 176–  182 (2012).\n 29. Serban, M.C. et al. Statin intolerance and risk of coronary heart \nevents and all-  cause mortality following myocardial infarction. J. \nAm. Coll. Cardiol.  69, 1386–  1395 (2017). 30. Cohen, J.D., Brinton, E.A., Ito, M.K. & Jacobson, T.A. \nUnderstanding Statin Use in America and Gaps in Patient \nEducation (USAGE): an internet-  based survey of 10,138 current \nand former statin users. J. Clin. Lipidol. 6 , 208–  215 (2012).\n 31. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, \nP.J. & Niemi, M. ABCG2 polymorphism markedly affects the \npharmacokinetics of atorvastatin and rosuvastatin. Clin. \nPharmacol. Ther.  86, 197–  203 (2009).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: I heard that I should avoid grapefruit or grapefruit juice as I am taking Lipitor, is this true? I love grapefruit, will getting a genetic test help me find another cholesterol drug that will not interact with grapefruit? Can you also tell me what your sources are for this information?

Answer: Yes, it's true that you should avoid grapefruit and grapefruit juice while taking Lipitor (atorvastatin). Grapefruit can increase the level of this drug in your body, which can raise the risk of side effects such as muscle pain or weakness. 

A genetic test might be helpful in this situation. It can provide information about how your body processes different drugs, including statins. This information can help your doctor choose a statin that is less likely to interact with grapefruit. However, it's important to note that genetic testing is just one tool that doctors use to guide their prescribing decisions. Your overall health, lifestyle, and other medications you're taking are also important factors.

As for my sources, I rely on a variety of trusted medical and scientific resources. These include the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, the FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, and the Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines. I also use research articles from reputable journals, such as the Clinical Pharmacology Therapeutics journal. 

Remember, it's always best to consult with your healthcare provider or a clinical pharmacist for personalized advice. They can provide the most accurate information based on your specific circumstances.
Sources:
page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='5 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang]  CYP2C9: (fluvastatin) AND (CYP2C9) HMGCR: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (HMGCR) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] CYP3A4/5: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR CYP3A5) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] Using these search terms, 1023 publications were identified. Study inclusion criteria included publications that incorporated analyses for the association between SLCO1B1, ABCG2, CYP2C9, HMGCR, or CYP3A4/5 genotypes and statins pharmacokinetic parameters as well as clinical outcomes. Non-English manuscripts and reviews were excluded. Following the application of these inclusion and exclusion criteria, 197 publications were reviewed and included in the evidence table (Table S1 to S5).  AVAILABLE GENETIC TEST OPTIONS  Desirable characteristics of pharmacogenetic tests, including naming of alleles and test report contents, have been' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='at 1-800-236-9933 or FDA at 1 -800-FDA- 1088 or www.fda.gov/medwatch.  \n---------------- --------------- DRUG INT ERACTIONS --------------------------- \n• Cyclosporine:  Combination increases rosuvastatin exposure. Limit \nCRESTOR dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3) \n• Gemfibroz il:  Combination should be avoided. If  used together, limit \nCRESTOR dose to 10 mg once daily. ( 2.4, 5.1, 7.2) \n• Ataz anavir/ritonavir, l opinavir/ ritonavir , or simeprevir:  Combination \nincreases rosuvastatin exposure. Limit CRESTOR dose to 10 mg once \ndaily. ( 2.4, 5.1, 7.3, 12.3) \n• Coumarin anticoagulants:  Combination prolongs INR. Achieve stable \nINR prior to starting CRESTOR. Monitor INR f requently until stable \nupon initiation or alteration of  CR ESTOR therapy. ( 5.3, 7.4) \n• Concomitant lipid -lowering therapies: Use with f ibrates or lipid -\nmodif ying doses (≥1 g/day) of  niacin increases the risk of  adverse \nskeletal muscle ef f ects. Caution should be used when prescribing with' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='Page 27 of 28Accepted Manuscript\n27 \n Figure 4 . Indications for  SLCO1B1  genotyping for simvastatin treatment. Proposed therapeutic strategy as a \nfunction of risk factors and current CPIC and FDA guidelines  [23,24].  \n 80 mg/J  \nMajor toxic risk  20  mg/J \nModerate toxic risk  \nAvoid combining with CYP3A and/or OATP1B1:  \n(Amiodarone,  amlodipine  ,  verapamil  ,  diltiazem  ,  gemfibrozil  ,  \nciclosporine, azoles  antifungals  ,  antiproteases  , …) \nA priori  SLCO1B genotyping  ? (potentially  useful test)  Dosage to avoid  \n(except  after prior 12 -month \nsatisfactory tolerance  \n SLCO1B1  genotype  \nunknown  \n 40 mg/J  \nIntermediary risk  \nTT TC CC \nLower simvastatin dose to 20 mg/d  \n+ CPK assay  \nOR therapeutic alternative  \n1) Fluvastatine  \n2) Lovastatine  \n3) Rosuvastatine  \n4) Atorvastatine  \n5) Pravastatine  \nMuscle toxicity:  \n discontinue treatment  \nSLCO1B1 genotyping  \nfor explanation  \n(potentially  useful test  Initiation of simvastatin treatement' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: I take Crestor for my cholesterol, and my husband and I are planning on having a baby. Can I continue taking Crestor during my pregnancy?

Answer: Hello! It's important to know that according to the FDA guidelines, Crestor (rosuvastatin calcium) is not recommended for use during pregnancy. The safety of Crestor in pregnant women has not been established, and there's no clear benefit to using Crestor during pregnancy. In fact, because Crestor decreases cholesterol synthesis, it could potentially harm the fetus if taken by a pregnant woman. If you become pregnant while taking Crestor, it's advised to stop the medication and contact your doctor right away. Always consult with your doctor for personalized medical advice.
Sources:
page_content='exercised when prescribing CRESTOR with colchicine [see Warnings and Prec autions  (5.1) ]. \n8 USE IN SPECIFIC POPULATIONS \n8.1 Pregnancy \nRisk Summary \nCRESTOR is contraindicated for use in pregnant women since safety in pregnant women has not \nbeen established and there is no apparent benefit to therapy with CRESTOR during pregnancy. \nBecause HMG -CoA reductase inhibitors decrease cholesterol synthesis and possibly the \nsynthesis of other biologically active substances derived from cholesterol, CRESTOR may cause \nfetal harm when administered to pregnant women. CRESTOR should be discontinued as soon as \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='• Do not  change your dose or stop CRESTOR without talking to your doctor, \neven if you are feeling well.  \n• Your doctor may do blood tests to check your cholesterol levels before and \nduring your treatment with CRESTOR. Your doctor may change your dose of CRESTOR if needed.  \n• Your doctor may start you on a cholesterol lowering diet before giving you CRESTOR. Stay on this diet when you take CRESTOR.  \n• Wait at least 2 hours after taking CRESTOR to take an antacid that contains a combination of aluminum and magnesium hydroxide.  \n• If you miss a dose of CRESTOR, take it as soon as you remember. However, \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='34 What should I tell m y doctor before and while taking CRESTOR?  \nTell your doctor if you:  \n• have unexplained muscle aches or weakness  \n• have or have had kidney problems  \n• have or have had liver problems  \n• drink more than 2 glasses of alcohol daily  \n• have thyroid problems  \n• are 65 years of a ge or older  \n• are of Asian descent  \n• are pregnant or think you may be pregnant, or are planning to become \npregnant  \n• are breastfeeding  \nTell your doctor about all the medicines you take,  including prescription and \nover-the-counter medicines, vitamins, and herbal  supplements.  \nTalk to your doctor before you start taking any new medicines.  \nTaking CRESTOR with certain other medicines may affect each other causing side \neffects. CRESTOR may affect the way other medicines work, and other medicines \nmay affect how CRESTO R works.  \nEspecially tell your doctor if you take:  \n• cyclosporine (a medicine for your immune system)' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='It is not known if CRESTOR is safe and effectiv e in people who have Fredrickson Type \nI and V dyslipidemias.  \nWho should not take CRESTOR?  \nDo not take CRESTOR if you:  \n• are allergic to rosuvastatin calcium or any of the ingredients in CRESTOR. See the end of this lea flet for a complete list of ingredients in CRESTOR.  \n• have liver problems.  \n• are pregnant or think you may be pregnant, or are planning to become \npregnant. CRESTOR may harm your unborn baby. If you become pregnant, \nstop taking CRESTOR and call your doctor righ t away.  If you are not planning \nto become pregnant you should use effective birth control (contraception) \nwhile you are taking CRESTOR.  \n• are breastfeeding. Medicines like CRESTOR can pass into your breast milk and \nmay harm your baby.  \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='The safety and effectiveness of CRESTOR in children and adolescents 10 to 17 years of age with \nheterozygous fami lial hypercholesterolemia were evaluated in a controlled clinical trial of \n12 weeks duration followed by 40 weeks of open-label exposure. Patients treated with 5  mg, \n10 mg, and 20 mg daily CRESTOR had an adverse experience profile generally similar to that  of \npatients treated with placebo. There was no detectable effect of CRESTOR on growth, weight, \nBMI (body mass index), or sexual maturation [see Clinical Studies (14. 7)] in children and \nadolescents  (10 to 17 years of age).  \nReference ID: 4347984' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='14 In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through \nlactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to \n12 times the M RHD of 40 mg/day based body surface area).  \nIn pregnant rabbits given 0.3, 1, and 3  mg/kg/day of rosuvastatin from gestation day 6 to da y 18, \ndecreased fetal viability and maternal mortality was observed at 3 mg/kg/ day (dose equivalent to \nthe MRHD of 40 mg/day based on body surface area).  \n8.2 Lactation \nRisk Summary \nRosuvastatin use  is contraindicated during breastfeeding [see Contraindications (4) ]. Limited \ndata indicate that CRESTOR  is present in  human milk. There is no available information on the \neffects of the drug on the breastfed infant or the effects of the drug on milk production. Because \nof the potential for serious adverse reactions in a breastfed infant, advise patients that \nbreastfeeding is not recommended during treatment with CRESTOR .' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of jaundice, for which a relationship to CRESTOR therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of liver failure \nor irreversible liver disease in these trials.  \nIn a poole d analysis of placebo-controlled trials, increa ses in serum transaminases to > 3 times \nthe upper limit of normal occurred in 1.1% of patients taking CRESTOR versus  0.5% of patients \ntreated with placebo.  \nThere have been rare postmarketing reports of fatal a nd non-fatal hepatic failure in patients \ntaking statins, including rosuvastatin. If serious liver injury with clinical symptoms and/or \nhyperbilirubinemia or jaundice occurs during treatment with CRESTOR, promptly interrupt \ntherapy. If an alternate etiology is not found, do not restart CRESTOR.  \nCRESTOR should be used with caution in patients who consume substantial quantities of' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='CRESTOR. ( 5.1, 7.5, 7.6) \n----------------------- USE IN SPECIFIC POP ULATIONS ------------------- -- \n• Females of reproductive potential:  Advise f emales of  reproductive \npotential to use ef f ective contraception during treatment with CRESTOR \n(8.3)  \n• Severe renal impairment (not on hemodialysis):   Starting dose is 5 mg,  \nnot to exceed 10 mg. ( 2.5, 5.1, 8.6) \n• Asian population: Consider 5 mg starting dose. ( 2.3, 8.8) \n See 17 for PATIENT COUNSELING INFORMATION and FDA-\napproved patient labeling . \nRevised: 9/2018\nFULL PRESCRIBING INFORMATION: CONTENTS\n*\n \n1 INDICATIONS AND USAG E \n1.1 Hyperlipidemia and Mixed Dyslipidemia  \n1.2 Pediatric Patients with Familial Hypercholesterolemia  \n1.3 Hypertriglyceridemia  \n1.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)  \n1.5 Adult Patients with Homozygous Familial Hypercholesterolemia  \n1.6 Slowing of  the Progression of  Atherosclerosis  \n1.7 Primary Prevention of  Cardiovascular Disease  \n1.8 Limitations of  Use' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='Adverse Reactions (6.1) ]. \nAlthough clinical studies have shown that CRESTOR alone does not reduce basal plasma cortisol concentration or impair adrenal reserve, caution should be exercised if CRESTOR is \nadministered concomitantly with drugs that may decrease the levels or activity of endogenous \nsteroid hormones such as ketoconazole, s pironolactone, and cimetidine.  \n6 ADVERSE REACTIONS  \nThe following serious adverse reactions are discussed in greater detail in other sections of the \nlabel:  \n• Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including \nmyositis) [see Warnings and Precautions (5.1) ] \n• Liver enzyme abnormalities [see Warnings and Precautions (5.2) ] \n6.1 Clinical Studies Experience \nBecause clinical studies are conducted under widel y varying conditions, adverse reaction rates \nobserved in the clinical studies of a drug cannot be directly compared to rates in the clinical' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='33  \nPATIENT INFORMATION  \nCRESTOR®(Kres-tor) \nrosuvastatin calcium  \nTablets  \nRead this Patient Information carefully before you start taking CRESTOR and each \ntime you get a refill. If you have any questions about CRESTOR, ask your doctor. \nOnly your doctor can determine if CRESTOR is right for you.  \nWhat is CRESTOR?  \nCRESTOR is a prescription medicine that contains a cholesterol -lowering medicine \ncalled rosuvastatin calcium . Most of the cholesterol in your blood is made in the liver. \nCRESTOR works by reducing cholesterol in two ways: CRESTOR blocks an  enzyme in \nthe liver causing the liver to make less cholesterol, and CRESTOR increases the \nuptake and breakdown by the liver of cholesterol already in the blood.  \n \n• CRESTOR is used along with diet to:  \no lower the level of your “bad” cholesterol (LDL)  \no increase the level of your “good” cholesterol (HDL)  \no lower the level of fat in your blood (triglycerides)' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='respectively . \nData \nHuman Data  \nLimited published data on r osuvastatin have not shown an increased risk of major congenital \nmalformations or miscarriage. Rare reports of congenital anomalies have been received \nfollowing intrauterine exposure to other statins. In a review of approximately 100 prospectively \nfollowed  pregnancies in women exposed to simvastatin or lovastatin, the incidences of \ncongenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what \nwould be expected in the general population. The number of cases is adequate to excl ude a ≥3 to \n4-fold increase in congenital anomalies over the background incidence.  In 89% of the \nprospectively followed pregnancies , drug treatment was initiated prior to pregnancy and was \ndiscontinued at some point in the first trimester when pregnancy wa s identified.  \nAnimal Data  \nRosuvastatin crosses the placenta in rats and rabbits  and is found in fetal tissue and amniotic' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}
page_content='• gemfibrozil (a fibric acid medicine for lowering cholesterol)  \n• anti-viral medicines including HIV or hepatitis  C protease inhibitors (such as \nlopinavir, rito navir, fosamprenavir, tipranavir, atazanavir, or simeprevir)  \n• certain anti -fungal medicines (such as itraconazole, ketoconazole and \nfluconazole)  \n• coumarin anticoagulants (medicines that prevent blood clots, such as \nwarfarin)  \n• niacin or nicotinic acid  \n• fibric a cid derivatives (such as fenofibrate)  \n• colchicine (a medicine used to treat gout)  \nAsk your doctor or pharmacist for a list of these medicines if you are not sure.  \nKnow all of the medicines you take. Keep a list of them to show your doctor and \npharmacist whe n you get new medicine.  \nHow should I take CRESTOR?  \n• Take CRESTOR exactly as your doctor tells you to take it.  \n• Take CRESTOR, by mouth, 1 time each day. Swallow the tablet whole.  \n• CRESTOR can be taken at any time of day, with or without food.' metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}


Question: My friend mentioned that red yeast rice can be a natural alternative to statins. Is this true?

Answer: Yes, that's correct. Red yeast rice is a type of fermented rice that is produced using a specific kind of mold. It's been used in traditional Chinese medicine for centuries and contains a substance called monacolin K, which is similar to the active ingredient in some statin medications. 

However, it's important to note that the amount of monacolin K in red yeast rice can vary a lot. This means that its effectiveness can also vary. Also, just like statins, red yeast rice can have side effects, including muscle pain and liver damage.

It's always a good idea to talk to your doctor before starting any new medication or supplement, including natural ones like red yeast rice. They can help you understand the potential benefits and risks, and decide what's best for your health.
Sources:
page_content='gemfibrozil increases systemic exposure to active simvastatin acid (36) placing patients at increased risk for developing myopathy. Because of interactions such as these, all the statin package labels recommend reducing the dose of statins in patients using concomitant medications known to alter its pharmacokinetics.   The Role of Ancestry.  There is some evidence that Asian Americans are one of three important groups with an elevated risk/benefit ratio for use of some statins compared to other ancestry groups; the other important groups were patients on cyclosporine (CSA)/immune suppression and patients with severe kidney failure) (37-43).Geographic differences in allele frequency for SLCO1B1 rs4149056 (c.521T>C) do not appear to contribute to this sensitivity in Asians (44). For rosuvastatin, this difference appears to be at least partly attributable to variability in efflux transporters such as ABCG2, as well as gene-gene and gene-environment interactions not yet defined (45).  For' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='other) genes, in addition to epigenetic, drug-  drug-  gene, and gene- \nenvironment interactions in statin therapies.\nDRUGS: STATINS (HMG-  CoA REDUCTASE INHIBITORS)\nBackground\nOne in four Americans aged 40 and older use a statin.24 In 2018, \natorvastatin and simvastatin were the #1 and #10 most commonly prescribed drugs in the United States, respectively. Statins have \na wide therapeutic index. The most common statin-  related ad -\nverse drug reaction is skeletal muscle toxicity which manifest \nas SAMS.25 SAMS include a range of clinical entities from the \nmost common (about 1 in 10), myalgia (pain without evidence of \nmuscle degradation, i.e., creatine kinase levels <\xa03× normal); less \ncommon (about 1 in 2,000), myopathy (evidence of muscle deg -\nradation with or without myalgia, i.e., creatine kinase levels ≥3× \nnormal); and rare (less than 1 in 10,000), rhabdomyolysis (severe \nmuscle damage with risk for acute kidney injury).26 Based on ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Clinical Genetically guided statin therapy improves patients’ perceptions of statins, more statin prescriptions, and lower LDL-C. Li, et al. (2014) (160) Peyser, et al. (2018) (161) Weak' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Page 16 of 28Accepted Manuscript\n16 \n risk, clopidogrel resistance, or statin muscle toxicity. These pharmacogenetic applications are \nsignificant in terms of bot h healthcare efficacy and pharmaco -economic impact, but further changes \nin clinical practices are still needed for widespread use. Finally, other tests whose levels of evidence  \nare still insufficient can be expected to be developed in the future. Potential ly they will concern \ndirect -action oral anticoagulants, aspirin, beta -blockers, or converting enzyme inhibitors.  \n \n \nDisclosure of interest  \nThe authors declare they have no conflict of interest  concerning this article.' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}
page_content='response to simvastatin. Arterioscler Thromb Vasc Biol  30, 1485-92 (2010).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Pharmacol. Ther.  86, 197–  203 (2009).\n 32. Chasman, D.I., Giulianini, F., MacFadyen, J., Barratt, B.J., Nyberg, \nF. & Ridker, P.M. Genetic determinants of statin-  induced low- \ndensity lipoprotein cholesterol reduction: the Justification for \nthe Use of Statins in Prevention: an Intervention Trial Evaluating \nRosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5 , 257–  264 \n(2012).\n 33. Wilke, R.A., Reif, D.M. & Moore, J.H. Combinatorial \npharmacogenetics. Nat. Rev. Drug Discov. 4 , 911–  918 (2005).\n 34. SEARCH Collaborative Group et al . SLCO1B1  variants and statin- \ninduced myopathy—  a genomewide study. N. Engl. J. Med. 359 , \n789–  799 (2008).\n 35. Wagner, J.B. et al. Impact of SLCO1B1  genetic variation on \nrosuvastatin systemic exposure in pediatric hypercholesterolemia. \nClin. Transl. Sci. 13 , 628–  637 (2020).\n 36. Wagner, J.B. et al. Impact of genetic variation on pravastatin \nsystemic exposure in pediatric hypercholesterolemia. Clin.' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='and atorvastatin therapy. Pharmacoepidemiol Drug Saf  19, 75-81 (2010).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='(as a function of statin type and dose, comedications, and the pathophysiological or genetic setting). \nIf the genotype is not known early, the RNPGx considers that a polymo rphism test is potentially \nuseful  in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a \ngenetic cause [12, 13].  \n \nConclusion s \n \nProgress achieved in recent years in the field of genetics has broadened our knowledge of the \nmolecular mechanisms implicated in the therapeutic response or the toxicity of drugs widely used \nfor cardiovascular diseases. The level of evidence  for pharmacoge netic tools available today is \nsufficient for clinical applications designed to predict and anticipate VKA resistance or hemorrhagic' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}
page_content='be incorrectly assigned a normal phenotype based on a default to \nwild- type ( *1) test result.\nIn summary, statins are a powerful class of medications for \nlowering LDL cholesterol and cardiovascular risk with an es-\ntablished track record of safety and efficacy. However, statin-  \nrelated musculoskeletal symptoms are the most frequently cited \nreason for discontinuing statin therapy. Although clinicians are \nwell-  tuned to trial stopping and later reinitiating statin therapy \nin those who develop SAMS, in many patients statin therapy is \nnever restarted. As a result, LDL cholesterol values are higher \nas is their risk for cardiovascular disease. W e applied a rigorous \napproach evaluating the collective evidence around SLCO1B1, \nABCG2, and CYP2C9 on systemic drug exposure and risk of \nSAMS. Our evidenced-  based recommendations for genotype-  \nguided statin therapy are focused on reducing the risk of SAMS. \nBased on this foundation, future research can evaluate the ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='extremely rare adverse effect from statin use. J Community Hosp Intern Med Perspect  9, 503-6 (2019). (210) Pocathikorn, A., Taylor, R.R. & Mamotte, C.D. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin Exp Pharmacol Physiol  37, 471-6 (2010). (211) Thompson, J.F. et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet  2, 173-81 (2009). (212) Poduri, A., Khullar, M., Bahl, A., Sehrawat, B.S., Sharma, Y. & Talwar, K.K. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol  29, 629-37 (2010). (213) Kirac, D. et al. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy. Cell Mol Biol (Noisy-le-grand)  63, 43-8 (2017). (214) Cuevas, A. et al. HMGCR rs17671591 SNP Determines Lower Plasma' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}


Question: I've been experiencing hair loss recently. Could this be related to my statin medication?

Answer: I'm sorry to hear about your hair loss. While it's not common, some people taking statin medications have reported hair loss as a side effect. However, many other factors can also cause hair loss, including stress, hormonal changes, or other health conditions. It's important to talk to your doctor about this. They can help determine if your hair loss might be related to your statin medication or if it could be due to something else. Remember, you should not stop taking your medication without consulting your doctor first.
Sources:
page_content='other) genes, in addition to epigenetic, drug-  drug-  gene, and gene- \nenvironment interactions in statin therapies.\nDRUGS: STATINS (HMG-  CoA REDUCTASE INHIBITORS)\nBackground\nOne in four Americans aged 40 and older use a statin.24 In 2018, \natorvastatin and simvastatin were the #1 and #10 most commonly prescribed drugs in the United States, respectively. Statins have \na wide therapeutic index. The most common statin-  related ad -\nverse drug reaction is skeletal muscle toxicity which manifest \nas SAMS.25 SAMS include a range of clinical entities from the \nmost common (about 1 in 10), myalgia (pain without evidence of \nmuscle degradation, i.e., creatine kinase levels <\xa03× normal); less \ncommon (about 1 in 2,000), myopathy (evidence of muscle deg -\nradation with or without myalgia, i.e., creatine kinase levels ≥3× \nnormal); and rare (less than 1 in 10,000), rhabdomyolysis (severe \nmuscle damage with risk for acute kidney injury).26 Based on ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='5 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang]  CYP2C9: (fluvastatin) AND (CYP2C9) HMGCR: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (HMGCR) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] CYP3A4/5: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='N.S., Neely, D., Avery, P., Brown, C., Daly, A.K. & Kamali, F. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther  104, 178-87 (2018). (136) Flores-Unzueta, S. et al. Simvastatin-related myopathy in shift workers: a report of two cases. Drug Metab Pers Ther  33, 153-6 (2018). (137) Carr, D.F. et al. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther  106, 1353-61 (2019). (138) S, C.T. et al. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. Biomarkers  24, 659-65 (2019). (139) Chan, J.C.M., Ng, M.H., Wong, R.S.M. & Tomlinson, B. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='myopathy. JAMA  289, 1681– 1690 (2003).\n 43. McClure, D.L., Valuck, R.J., Glanz, M., Murphy, J.R. & Hokanson, \nJ.E. Statin and statin-  fibrate use was significantly associated \nwith increased myositis risk in a managed care population. J. Clin. \nEpidemiol.  60, 812–  818 (2007).\n 44. Link, E. et al. SLCO1B1  variants and statin-  induced myopathy–  a \ngenomewide study. N. Engl. J. Med. 359 , 789–  799 (2008).\n 45. Ananthakumar, A., Liu, Y., Fernandez, C.E., Truskey, G.A. & \nVoora, D. Modeling statin myopathy in a human skeletal muscle \nmicrophysiological system. PLoS One  15, e0242422 (2020).\n 46. Osaki, Y. et al. Skeletal muscle-  specific HMG-  CoA reductase \nknockout mice exhibit rhabdomyolysis: a model for statin-  induced \nmyopathy. Biochem. Biophys. Res. Commun. 466 , 536–  540 \n(2015).\n 47. Schirris, T.J.J. et al. Statin-  induced myopathy is associated with \nmitochondrial complex III inhibition. Cell Metab.  22, 399–  407 \n(2015).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='continuation, thus leading to higher cholesterol levels and a higher \nrisk for cardiovascular disease if statins are not reinitiated.29,30\nLinking genetic variability to variability in drug-  related \nphenotypes\nWe applied a systematic approach to reviewing the evidence un -\nderlying the clinical validity of genetic associations with statin- \nrelated phenotypes including statin pharmacokinetics ( in vivo  \nand in vitro ), SAMS, hepatotoxicity, lab-  based efficacy (choles -\nterol lowering), and clinical efficacy (vascular event reduction). \nStatins evaluated included simvastatin, rosuvastatin, pravastatin, \npitavastatin, atorvastatin, fluvastatin, and lovastatin. We reviewed \nthe evidence for SLCO1B1 , ABCG2 , CYP2C9 , CYP3A4/5 , and \nHMGCR  and applied a grading system for each piece of evi -\ndence that evaluated an association between genotype and phe -\nnotype ( Tables\xa0 S1–  S5). We found the highest levels of evidence \nfor SLCO1B1  (all statins), ABCG2  (rosuvastatin), and CYP2C9' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='27. Abd, T.T. & Jacobson, T.A. Statin-  induced myopathy: a review and \nupdate. Expert Opin. Drug Saf. 10 , 373–  387 (2011).\n 28. Buettner, C., Rippberger, M.J., Smith, J.K., Leveille, S.G., Davis, R.B. \n& Mittleman, M.A. Statin use and musculoskeletal pain among adults \nwith and without arthritis. Am. J. Med. 125, 176–  182 (2012).\n 29. Serban, M.C. et al. Statin intolerance and risk of coronary heart \nevents and all-  cause mortality following myocardial infarction. J. \nAm. Coll. Cardiol.  69, 1386–  1395 (2017). 30. Cohen, J.D., Brinton, E.A., Ito, M.K. & Jacobson, T.A. \nUnderstanding Statin Use in America and Gaps in Patient \nEducation (USAGE): an internet-  based survey of 10,138 current \nand former statin users. J. Clin. Lipidol. 6 , 208–  215 (2012).\n 31. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, \nP.J. & Niemi, M. ABCG2 polymorphism markedly affects the \npharmacokinetics of atorvastatin and rosuvastatin. Clin. \nPharmacol. Ther.  86, 197–  203 (2009).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='be incorrectly assigned a normal phenotype based on a default to \nwild- type ( *1) test result.\nIn summary, statins are a powerful class of medications for \nlowering LDL cholesterol and cardiovascular risk with an es-\ntablished track record of safety and efficacy. However, statin-  \nrelated musculoskeletal symptoms are the most frequently cited \nreason for discontinuing statin therapy. Although clinicians are \nwell-  tuned to trial stopping and later reinitiating statin therapy \nin those who develop SAMS, in many patients statin therapy is \nnever restarted. As a result, LDL cholesterol values are higher \nas is their risk for cardiovascular disease. W e applied a rigorous \napproach evaluating the collective evidence around SLCO1B1, \nABCG2, and CYP2C9 on systemic drug exposure and risk of \nSAMS. Our evidenced-  based recommendations for genotype-  \nguided statin therapy are focused on reducing the risk of SAMS. \nBased on this foundation, future research can evaluate the ex -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='extremely rare adverse effect from statin use. J Community Hosp Intern Med Perspect  9, 503-6 (2019). (210) Pocathikorn, A., Taylor, R.R. & Mamotte, C.D. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin Exp Pharmacol Physiol  37, 471-6 (2010). (211) Thompson, J.F. et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet  2, 173-81 (2009). (212) Poduri, A., Khullar, M., Bahl, A., Sehrawat, B.S., Sharma, Y. & Talwar, K.K. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol  29, 629-37 (2010). (213) Kirac, D. et al. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy. Cell Mol Biol (Noisy-le-grand)  63, 43-8 (2017). (214) Cuevas, A. et al. HMGCR rs17671591 SNP Determines Lower Plasma' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='response to simvastatin. Arterioscler Thromb Vasc Biol  30, 1485-92 (2010).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='U. & Krossnes, B.K. Persisting weakness after withdrawal of a statin. BMJ Case Rep  2014,  (2014). (196) Ong, S.G. & Ding, H.J. Patient with statin-associated immune-mediated necrotizing myopathy presenting with subcutaneous edema, persistent bulbar weakness and absent anti-HMGCR. Int J Rheum Dis  20, 2175-8 (2017). (197) Karunaratne, K., Amiras, D., Pickering, M.C., Hofer, M. & Viegas, S. Autoimmune necrotising myopathy and HMGCR antibodies. Pract Neurol  18, 151-5 (2018). (198) Pitlick, M. & Ernste, F. Anti-HMGCR myopathy presenting with acute systolic heart failure. BMJ Case Rep  12,  (2019). (199) Krauss, R.M. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation  117, 1537-44 (2008). (200) Mangravite, L.M. et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='ciclosporin. Nephron  65, 410-3 (1993). (61) Ide, T., Sasaki, T., Maeda, K., Higuchi, S., Sugiyama, Y. & Ieiri, I. Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. Journal of clinical pharmacology  49, 1309-17 (2009). (62) Werner, M., Sacher, J. & Hohenegger, M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol  143, 715-24 (2004). (63) Sacher, J., Weigl, L., Werner, M., Szegedi, C. & Hohenegger, M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther  314, 1032-41 (2005). (64) Dirks, A.J. & Jones, K.M. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol  291, C1208-12 (2006). (65) Maggo, S.D., Kennedy, M.A. & Clark, D.W. Clinical implications of' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


